Business ❯ Biotechnology

Pharmaceuticals

Drug Development Acquisitions Clinical Trials Vaccine Development Oncology Cancer Treatment Biosimilars Gene Therapy Regulatory Affairs Biopharmaceuticals

BioNTech Founders to Exit and Launch New mRNA Venture as Shares Sink on Weak Outlook

The new company will receive select mRNA rights in exchange for a minority stake plus milestone and royalty payments.

Stories older than 24h

Vertex’s IgA Nephropathy Drug Hits Phase 3 Goals, FDA Filing Slated for March

FDA to Review Moderna’s Flu Shot as Shares Rally on Earnings Beat

Astellas–Vir Prostate Cancer Alliance Launches With New Data as VIR Stock Surges

Gilead to Acquire Arcellx for Up to $7.8 Billion to Gain Full Control of CAR-T Anito-Cel

Compass Pathways’ Psilocybin Therapy Hits Phase 3 Goal in Treatment-Resistant Depression

Vertex Heads Into Feb. 12 Earnings With Cautious Market After Mixed Year

Biogen Guides 2026 Profit Above Estimates on Cost Cuts and Leqembi Momentum

CEPI Taps Samsung Biologics to Pre-Position Rapid Vaccine Manufacturing for Future Outbreaks

Genentech Licenses SanegeneBio RNAi Program in Deal Worth Up to $1.7 Billion

Lilly, Repertoire Strike Up-to-$1.93 Billion Autoimmune Drug Pact

Sarepta Reports 3-Year EMBARK Data Showing Elevidys Slows Duchenne Progression

Bristol Myers, Janux Strike Exclusive Deal on Tumor-Activated T-Cell Engager

ImmunityBio Sets 30-Day FDA Submission After Positive Meeting on Anktiva Expansion

Genentech Lifts Holly Springs Biomanufacturing Plan to $2 Billion, Over 500 Jobs

Rakuten Medical, Lotte Biologics Sign Manufacturing Deal for Photoimmunotherapy Supply

Eupraxia Reports Early EoE Trial Data With Near‑Normal Tissue at Top Dose

Amgen Buys Oxford Spinout Dark Blue Therapeutics for Up to $840 Million

Zymeworks and BeOne Say Phase 3 Zanidatamab Regimens Top Two Years’ Survival in First-Line HER2+ GEA

Genmab Halts Acasunlimab to Focus on Late-Stage Cancer Portfolio